Heart failure & cardiomyopathies
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy
Study context
- Population
- T2DM patients with diabetic cardiomyopathy at high risk of progression to overt heart failure (HF)fully enrolled
- Participants
- 675 patients
- Planned comparison
- AT-001 vs placebo
- Primary endpoint
- Exercise capacity: change in peak VO2
- Follow-up
- 15 (and possibly 27) months
Methodological detailsPhase 3, placebo-controlled, double-blind, global, Additional endpoints: progression to overt HF, health status, echocardiographic measures, cardiac biomarkers
- Phase 3
- Placebo-controlled
- Double-blind
- Global
- Additional endpoints: progression to overt HF, health status, echocardiographic measures, cardiac biomarkers
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. Am Heart J. Published 11 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →